Bone resorption inhibitors

The calcium-binding properties of pamidronate, a bone-resorption inhibitor.

Bone resorption is resorption of bone tissue, that is, the process by which osteoclasts break down the tissue in bones [1] Bisphosphonates, RANKL inhibitors

Bisphosphonates are inhibitors of bone resorption. They increase bone mineral density by altering osteoclast activation and function. Alendronate and

As a consequence, bone resorption is inhibited. High OPG levels protect bones from resorption . Therapeutic administration of OPG to women suffering from postmenopausal osteoporosis caused a decrease in bone resorption markers by 80% . RANKL/RANK signaling inhibitors are believed to play an important role in preventing bone loss.

by S Zhou 2024 Cited by 48Currently, the main therapeutic drugs for osteoporosis are bone resorption inhibitors [[115], [116], [117]]. These drugs inhibit bone resorption

Romosozumab is a new class of osteoporosis treatment, a sclerostin inhibitor that both increases bone formation and decreases bone resorption. Romosozumab (

All bisphosphonates inhibit bone resorption by attaching to hydroxyapatite binding sites on the bone, particularly in areas with active resorption. As osteoclasts resorb bone, the bisphosphonate embedded in the bone is released and impairs the osteoclast s ability to continue bone resorption.

Bone resorption is resorption of bone tissue, that is, the process by which osteoclasts break down the tissue in bones [1] Bisphosphonates, RANKL inhibitors

5 ALFA REDUCTASE INHIBITORS. , IMMUNOMODULATORY AGENTS. , BONE RESORPTION INHIBITORS. , COMPLEMENT INHIBITORS. , DISEASE-MODIFYING